BioSpace News Archive

Ablacon, Inc., an Ajax Health-backed company, announced the close of a $30 million Series B financing, with Zeus Health joining as new lead investor.

Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, announced today that it has completed enrollment and dosing in the dose cohorts comprising the second interim data analysis from its Phase 1/2 clinical trial for MRT5005 in cystic fibrosis (CF).

Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, today announced the last patient visit in its GB-102 Phase 2b ALTISSIMO core trial (the 12-month treatment phase) in wet age-related macular degeneration (wet AMD). ALTISSIMO 12-month topline data are expected to be announced in the second quarter of 2021

Alcami, a leading United States-based contract development and manufacturing organization, announced an additional $2 million investment to expand its oral solid development and manufacturing capabilities in Wilmington, NC.

The platelet concentration systems market is expected to gain promising growth across the assessment period of 2020-2030.

Orismilast is a next generation oral PDE4-inhibitor with an improved therapeutic window compared to other PDE4-inhibitors

Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc., to provide access to Avacta’s pre|CISION technology for the development of tumour-activated radiopharmaceuticals.

RVO, an agency of the Dutch Ministry of Economic Affairs and Climate Policy, provides a loan of up to €5 million for the COVID-19 cohort clinical study

TransCon ™ C-Type Natriuretic Peptide (CNP), an investigational once-weekly long-acting prodrug of CNP, is ready for Phase 2 Clinical Trial in China

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, announced that John Bencich, Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference being held virtually January 11-14, 2021.